# You Lü

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/you-lu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 12,414 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 53 |
| i10-index | 176 |
| Last Known Institution | University of New Orleans |
| OpenAlex ID | https://openalex.org/A5100460392 |
| ORCID iD | 0000-0003-1671-1408 |
| Works | 430 |

## Researcher papers

- [Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues](https://scholariq.org/papers/clades-of-adeno-associated-viruses-are-widely-disseminated-in-human-tissues/)
- [Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer](https://scholariq.org/papers/safety-and-feasibility-of-crispr-edited-t-cells-in-patients-with-refractory-non/)
- [Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial](https://scholariq.org/papers/gefitinib-plus-chemotherapy-versus-placebo-plus-chemotherapy-in-egfr-mutation/)
- [Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)](https://scholariq.org/papers/efficacy-and-safety-of-sintilimab-plus-pemetrexed-and-platinum-as-first-line/)
- [BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/beyond-a-randomized-double-blind-placebo-controlled-multicenter-phase-iii-study/)
- [Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial](https://scholariq.org/papers/nivolumab-versus-docetaxel-in-a-predominantly-chinese-patient-population-with/)
- [Adeno-associated viruses undergo substantial evolution in primates during natural infections](https://scholariq.org/papers/adeno-associated-viruses-undergo-substantial-evolution-in-primates-during/)
- [AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations](https://scholariq.org/papers/aeneas-a-randomized-phase-iii-trial-of-aumolertinib-versus-gefitinib-as-first/)
- [Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)](https://scholariq.org/papers/anlotinib-as-a-third-line-therapy-in-patients-with-refractory-advanced-non-small/)
- [Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer](https://scholariq.org/papers/randomized-trial-of-first-line-tyrosine-kinase-inhibitor-with-or-without/)
- [Pseudo-small cell transformation in EGFR-mutant adenocarcinoma](https://scholariq.org/papers/pseudo-small-cell-transformation-in-egfr-mutant-adenocarcinoma/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)

## Researcher university

- [University of New Orleans](https://scholariq.org/institutions/university-of-new-orleans/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.